Express Scripts added Milestone Pharmaceuticals' newly approved CARDAMYST nasal spray to its commercial national formularies, materially expanding access for adults with paroxysmal supraventricular tachycardia. Broader formulary coverage should lift potential patient uptake and prescription volumes, providing a modest revenue tailwind for Milestone (MIST). Expect limited near-term share movement but improved commercial visibility and longer-term uptake as access widens.
Express Scripts added Milestone Pharmaceuticals' newly approved CARDAMYST nasal spray to its commercial national formularies, materially expanding access for adults with paroxysmal supraventricular tachycardia. Broader formulary coverage should lift potential patient uptake and prescription volumes, providing a modest revenue tailwind for Milestone (MIST). Expect limited near-term share movement but improved commercial visibility and longer-term uptake as access widens.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
